First Measles Case of the Year Reported in New Jersey
Medically reviewed by Drugs.com
via HealthDayFRIDAY, April 24, 2026 — Health officials in New Jersey are warning folks of possible measles exposure after confirming the state’s first case of the year.
The infection was found in a Hudson County resident who recently traveled abroad, NJ.com reported.
People who were at certain locations in mid-April may have been exposed. These include:
Officials say symptoms could show up as late as May 11.
Measles spreads easily through coughing and sneezing. The virus can stay in the air for up to two hours after an infected person leaves, according to the U.S. Centers for Disease Control and Prevention (CDC).
Early signs include a high fever, cough, runny nose and red, watery eyes. A red rash that starts at the hairline usually appears three to five days later.
People can spread the virus from four days before the rash appears to four days after, the CDC says.
Anyone who may have been exposed and feels sick should call a doctor before seeking care in person, officials said.
This helps prevent the virus from spreading to others.
Measles cases are rising across the country. As of April 16, the latest available data, the CDC had reported 1,748 confirmed cases in the United States.
What's more, about 92% of cases are in people who are unvaccinated or whose vaccination status is unknown.
Experts say the measles, mumps and rubella (MMR) vaccine is the best protection. Two doses are recommended: One at 12 to 15 months of age and another at 4 to 6 years old.
Sources
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2026-04-25 01:43
Read more
- What Sea Creatures Reveal About How Fast People Age
- New Guidelines Issued for Anticoagulant Prophylaxis for Pediatric VTE
- Double Shifts Disrupt Normal Cortisol Patterns
- Phase III Study Results with Bayer’s FXIa Inhibitor Asundexian Demonstrating Substantial Reduction in Ischemic Stroke with No Increase in ISTH Major Bleeding Versus Placebo Published in New England Journal of Medicine
- Cough Drops From Several Brands Being Recalled, FDA Says
- FDA Approves Ponlimsi (denosumab-adet), a Biosimilar to Prolia
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions